ArticlemBio2020
Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 96 citations in OpenAlex.
- No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCT.Frontiers in immunology · 2025Trial
- Effectiveness and Immunogenicity of the MMR Vaccine Against SARS-CoV-2 Among Healthcare Workers.Viruses · 2025Article
- The underlying mechanism behind the different outcomes of COVID-19 in children and adults.Frontiers in immunology · 2025Review
- The Influence of Cross-Reactive T Cells in COVID-19.Biomedicines · 2024Review
- Analysis of Measles and Rubella Immunoglobulin G Titers in COVID-19 Patients.Risk management and healthcare policy · 2024Article
- Impact of the COVID-19 pandemic on routine vaccine landscape: A global perspective.Human vaccines & immunotherapeutics · 2023Review
- Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?Archivum immunologiae et therapiae experimentalis · 2023Article
- Review
- The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.Nature reviews. Immunology · 2023Review
- Recent developments in the immunopathology of COVID-19.Allergy · 2023Review
- Effect of MMR Vaccination to Mitigate Severe Sequelae Associated With COVID-19: Challenges and Lessons Learned.Medical research archives · 2023Article
- Stable Levels of Antibodies Against Unrelated Toxoid Vaccines After COVID-19: COVID-19 Infection Does Not Affect Toxoid Vaccine Antibody Levels.Pathogens & immunity · 2023Article
- Human health implications of emerging diseases and the current situation in India's vaccine industry.Science in One Health · 2023Review
- Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study.Vaccines · 2022Article
- Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic.World journal of virology · 2022Review
- SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era.Virology journal · 2022Review
- A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- U.S. CDC support to internationalPLOS global public health · 2022Article
- Does the rubella immunoglobulin G affect the severity of COVID- 19? : Rubella immunoglobulin G and COVID- 19.BMC microbiology · 2022Article
- The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against coronavirus disease 2019 (COVID-19). Our aim was to determine whether any MMR IgG titers are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with MMR II. We divided 80 subjects into two groups, comparing MMR titers to recent COVID-19 severity levels. The MMR II group consisted of 50 subjects who would primarily have MMR antibodies from the MMR II vaccine, and a comparison group of 30 subjects consisted of those who would primarily have MMR antibodies from sources other than MMR II, including prior measles, mumps, and/or rubella illnesses. There was a significant inverse correlation (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.